Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Hydroxychloroquine
Drug ID BADD_D01103
Description Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer.[A183047] Hydroxychloroquine is an aminoquinoline like [chloroquine].[L8072] It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus.[L8072] Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely.[L8072] It was developed during World War II as a derivative of [quinacrine] with less severe side effects.[A183092] Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2.[A192132] **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.[L14312]** Hydroxychloroquine was granted FDA approval on 18 April 1955.[L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546]
Indications and Usage For the suppressive treatment and treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also indicated for the treatment of discoid and systemic lupus erythematosus, and rheumatoid arthritis.
Marketing Status Prescription; Discontinued
ATC Code P01BA02
DrugBank ID DB01611
KEGG ID D08050
MeSH ID D006886
PubChem ID 3652
TTD Drug ID D0OJ4L
NDC Product Code Not Available
Synonyms Hydroxychloroquine | Oxychlorochin | Oxychloroquine | Hydroxychlorochin | Plaquenil | Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate (1:1) Salt
Chemical Information
Molecular Formula C18H26ClN3O
CAS Registry Number 118-42-3
SMILES CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic function abnormal09.01.02.001--Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.000405%Not Available
Hepatitis09.01.07.0040.000607%Not Available
Hepatitis B11.05.06.002; 09.01.09.0030.000158%
Hepatitis C11.05.06.004; 09.01.09.0050.000405%Not Available
Hepatitis fulminant09.01.07.007; 11.07.01.003--Not Available
Hepatocellular injury09.01.07.0080.001417%Not Available
Hepatomegaly09.01.05.0010.000405%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.000607%Not Available
Herpes zoster11.05.02.003; 23.09.03.0020.000405%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkeratosis23.01.01.0010.000405%
Hypersensitivity10.01.03.0030.009718%
Hypertension24.08.02.001--
Hypertensive crisis24.08.01.0010.000405%Not Available
Hypoaesthesia17.02.06.0230.001417%Not Available
Hypoaesthesia eye17.02.06.019; 06.01.01.007--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.001215%
Hypokalaemia14.05.03.0020.001822%
Hypokinesia17.01.02.009--Not Available
Hypotension24.06.03.002--
Hypoxia22.02.02.0030.000158%
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.0100.000607%
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Irritability08.01.03.011; 19.04.02.013--
Joint effusion15.01.02.0050.000405%
Joint swelling15.01.02.0040.001215%Not Available
Left ventricular failure02.05.02.0010.000607%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages